Taurocholic acid controlled-release - Satiogen Pharmaceutical

Drug Profile

Taurocholic acid controlled-release - Satiogen Pharmaceutical

Alternative Names: Conjugated bile acids sodium - Satiogen Pharmaceutical; Ox bile extract - Satiogen Pharmaceutical; Taurocholic acid delayed-release - Satiogen Pharmaceutical

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Satiogen Pharmaceuticals
  • Developer Mayo Clinic; Satiogen Pharmaceuticals
  • Class Antihyperglycaemics; Cholic acids; Obesity therapies; Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 15 Sep 2016 Chemical structure information added
  • 01 Aug 2016 Phase-II clinical trials in Obesity in USA (PO) (NCT02871882)
  • 01 Aug 2016 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO) (NCT02871882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top